Yvonne Diaz
@yvonne_diaz_
Comms professional. Mum to twin sons & a dog. Living w stage 4 ALK+ #lungcancer. Co-founder @OncogeneCancer. Board Member @ALKPositiveInc #ResearchMatters #LCSM
ID: 1515061275088150528
https://instagram.com/yvonne_diaz_lc?igshid=OGQ5ZDc2ODk2ZA== 15-04-2022 20:15:47
2,2K Tweet
1,1K Followers
862 Following
We have 2 trials of bispecific antibodies in lung cancer open and running Chelsea and Westminster Hospital In fact, recruited the first patients in Europe to both of these 🦸
🫁Radioligand Therapy Offers Hope to Lung Cancer Patients - Oncogene Cancer Research oncodaily.com/insight/148167 #Cancer #LCSM #CancerTreatment #Innovation #MedEd #MedNews #Health #Medicine #MedTwitter #OncoDaily #Oncology
Fantastic work from Davare Lab on oncogenic potential of #ROS1 extracellular domain (ECD) which doesn’t necessarily require fusion partner to sustain oncogenesis. The ROS1ders, Inc.
Nice to be recognised! Of course I am just one of a bigger team! Uganda Cancer Institute
Tonight's ALKtALK with Dr. JessicaJLinMD has just kicked off at the earlier time than usual. Do join us to hear all the latest research unveiled during #WCLC24 & #ESMO24, and a general talk on all things ALK lung cancer. Join us now: 👉alkpositive.org/alktalk
Following the latest CROWN data, those w ALK lung cancer want to understand what resistance to first line Lorlatinib looks like & any next 2L therapy. While the data is not quite there, Dr. JessicaJLinMD shared this initial info from #WCLC24. The ALKtALK replay out soon. #LCSM
Yvonne Diaz JessicaJLinMD IASLC ESMO - Eur. Oncology MassGeneral News Summer Farmen At last evening's ALKtALK, this chart generated a lot of questions. Important to understand why not all ALK patients move to a second line inhibitor after their first line treatment. Stay tuned for the replay of our ALKtALK - out this week. Thanks Dr. JessicaJLinMD! #LCSM
TODAY IS THE DEADLINE for submitting abstracts for the EGFR Resisters Research Summit! #EGFR EGFR Resisters #LCSM
Repurposing approved meds may speed up options for patients. Gilteritinib is FDA-approved for FLT3-mutated AML. U-M Rogel Cancer Center is studying use of gilteritinib in ALK. Article shows cholesterol inhibition enhances response of gilteritinib in lung cancer👇 nature.com/articles/s4141…
Systematic review & network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as 1L treatment for advanced ALK-NSCLC. lungcancerjournal.info/article/S0169-… ALK+ International ALK Positive LCAM Coalition
Great interactive day 2 at the Lung Cancer Europe Members meeting sharing best practice and there have been some great initiatives we have heard about. Great being one of the ‘oncogene girls’ representing the UK 😉EGFR Positive Lung Cancer UK Oncogene Cancer Research Lung Cancer Europe
Two brilliant days with this exceptional group of individuals. Thank you to our speakers, members, executive team & our moderator/facilitator - Kathy Redmond. Special thanks to my fellow board members. It's my privilege serving as your Lung Cancer Europe president ❤️
Great to see a blood test for the detection of lung cancer is one step closer w the work from University of York’s Cizzie Biotech & Moffitt Cancer Center. Based on the discovery of the CIZ1B biomarker. A step fwd in early detection. york.ac.uk/news-and-event…